Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Major Shareholder Sells 1,191 Shares of Stock

Friday, June 11, 2021 | MarketBeat

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) major shareholder Pharmaceutical Co Ltd Takeda sold 1,191 shares of the business's stock in a transaction on Wednesday, June 9th. The shares were sold at an average price of $35.28, for a total transaction of $42,018.48. Following the sale, the insider now directly owns 940,814 shares in the company, valued at $33,191,917.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Pharmaceutical Co Ltd Takeda also recently made the following trade(s):

  • On Monday, June 7th, Pharmaceutical Co Ltd Takeda sold 2,264 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $35.05, for a total transaction of $79,353.20.
  • On Tuesday, June 1st, Pharmaceutical Co Ltd Takeda sold 11,211 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $35.78, for a total transaction of $401,129.58.
  • On Friday, May 28th, Pharmaceutical Co Ltd Takeda sold 8,905 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $36.19, for a total transaction of $322,271.95.
  • On Wednesday, May 26th, Pharmaceutical Co Ltd Takeda sold 12,358 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $36.64, for a total transaction of $452,797.12.
  • On Wednesday, May 26th, Pharmaceutical Co Ltd Takeda sold 12,358 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $36.64, for a total transaction of $452,797.12.
  • On Monday, May 24th, Pharmaceutical Co Ltd Takeda sold 10,594 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $35.66, for a total transaction of $377,782.04.
  • On Thursday, May 20th, Pharmaceutical Co Ltd Takeda sold 7,098 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $35.10, for a total transaction of $249,139.80.
  • On Friday, May 14th, Pharmaceutical Co Ltd Takeda sold 100 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $35.00, for a total transaction of $3,500.00.
  • On Wednesday, May 12th, Pharmaceutical Co Ltd Takeda sold 11,776 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $35.44, for a total transaction of $417,341.44.
  • On Friday, May 7th, Pharmaceutical Co Ltd Takeda sold 1,011 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $35.03, for a total transaction of $35,415.33.

Phathom Pharmaceuticals stock opened at $34.92 on Friday. The company has a 50 day moving average price of $36.16. Phathom Pharmaceuticals, Inc. has a 1-year low of $28.10 and a 1-year high of $51.70. The company has a debt-to-equity ratio of 0.22, a quick ratio of 5.94 and a current ratio of 5.94. The stock has a market cap of $1.09 billion, a PE ratio of -8.31 and a beta of 1.14.

Phathom Pharmaceuticals (NASDAQ:PHAT) last posted its quarterly earnings results on Tuesday, May 11th. The company reported ($0.96) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.15. On average, research analysts forecast that Phathom Pharmaceuticals, Inc. will post -3.65 earnings per share for the current year.

Several research analysts recently weighed in on the stock. BMO Capital Markets assumed coverage on shares of Phathom Pharmaceuticals in a research report on Wednesday, February 17th. They set an "outperform" rating and a $63.00 price target for the company. Zacks Investment Research upgraded shares of Phathom Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, June 3rd. Finally, The Goldman Sachs Group upgraded shares of Phathom Pharmaceuticals from a "sell" rating to a "neutral" rating and increased their price objective for the company from $40.00 to $48.00 in a report on Wednesday, May 12th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Phathom Pharmaceuticals currently has an average rating of "Buy" and an average price target of $53.00.

Institutional investors have recently bought and sold shares of the company. Royal Bank of Canada purchased a new stake in shares of Phathom Pharmaceuticals in the 1st quarter valued at approximately $25,000. Cutler Group LP purchased a new position in shares of Phathom Pharmaceuticals during the 1st quarter worth approximately $26,000. Citigroup Inc. boosted its position in shares of Phathom Pharmaceuticals by 194.6% during the 4th quarter. Citigroup Inc. now owns 3,294 shares of the company's stock worth $110,000 after purchasing an additional 2,176 shares during the period. Chicago Partners Investment Group LLC purchased a new position in shares of Phathom Pharmaceuticals during the 1st quarter worth approximately $206,000. Finally, Trexquant Investment LP purchased a new position in shares of Phathom Pharmaceuticals during the 4th quarter worth approximately $208,000. 77.06% of the stock is owned by institutional investors and hedge funds.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.

Featured Story: Basic Economics

Insider Buying and Selling by Quarter for Phathom Pharmaceuticals (NASDAQ:PHAT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: What is a Futures Contract?


7 Forever Stocks That Are Never Bad to Buy

Investors thought 2021 would be a less volatile year. That narrative has run into some problems. Sure, all the major indexes are up for the year. And that’s despite the NASDAQ’s gut-wrenching 10% drop in March.

But many investors don’t feel much like celebrating. In fact, many are concerned about the liquidity that continues to be pumped into the stock market. In 2020, the pandemic flooded the economy with $6 trillion dollars of stimulus.

However, in the last few months, the Federal Reserve has introduced another $6 trillion into the economy. We would have stopped counting, but the math is pretty easy. It’s $12.3 trillion that has flooded into the economy.

Eventually, this is going to end badly. But timing the market is an imperfect science particularly when many investors are enjoying the game.

Fortunately, there’s a way to safeguard your portfolio without abandoning equities. That has to do with investing in forever stocks. Forever stocks aren’t magic beans. They don’t go up forever. But they are stocks that have stood the test of time. And investing in these stocks will keep your portfolio heading in the right direction.

With that in mind, we’ve put together this special presentation that showcases seven of these forever stocks. These are all stocks that are household names, but that’s kind of the point. You don’t need special knowledge. You just have to recognize that these are companies that consistently do right by their shareholders.

View the "7 Forever Stocks That Are Never Bad to Buy".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.